The role of NPY and Ghrelin in anorexia nervosa

Current Pharmaceutical Design

Volumn 18, Issue 31, 2012, Pages 4766-4778

  Zhang, Lei ^a   Yagi, Miyuki ^a   Herzog, Herbert ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Anorexia; Energy homeostasis; Ghrelin; Neuropeptide Y (NPY) family; Osteoporosis

Indexed keywords

GHRELIN; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; PEPTIDE YY;

ANOREXIA NERVOSA; ENERGY EXPENDITURE; ENERGY HOMEOSTASIS; FEEDING BEHAVIOR; HOMEOSTASIS; HUMAN; INCREASED APPETITE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANOREXIA NERVOSA; APPETITE REGULATION; BONE AND BONES; ENERGY METABOLISM; GHRELIN; HOMEOSTASIS; HUMANS; NEURONS; NEUROPEPTIDE Y; OSTEOPOROSIS; PANCREATIC POLYPEPTIDE; PEPTIDE YY; PROTEIN PRECURSORS; RECEPTORS, GHRELIN; RECEPTORS, NEUROPEPTIDE Y; SIGNAL TRANSDUCTION;

EID: 84866422730     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803216988     Document Type: Review

References (172)

1. Pinhas L, Morris A, Crosby RD, Katzman DK. Incidence and agespecific presentation of restrictive eating disorders in children: a Canadian Paediatric Surveillance Program study. Arch Pediatr Adolesc Med 2011; 165(10): 895-899.
2. Rosling AM, Sparen P, Norring C, von Knorring AL. Mortality of eating disorders: a follow-up study of treatment in a specialist unit 1974-2000. Int J Eat Disord 2011; 44(4): 304-310.
3. Forcano L, Alvarez E, Santamaria JJ, et al. Suicide attempts in anorexia nervosa subtypes. Compr Psychiatry 2011; 52(4): 352-358.
4. Preti A, Rocchi MB, Sisti D, Camboni MV, Miotto P. A comprehensive meta-analysis of the risk of suicide in eating disorders. Acta Psychiatr Scand 2011; 124(1): 6-17.
5. Sahu A. Evidence suggesting that galanin (GAL), melaninconcentrating hormone (MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. Endocrinology 1998; 139(2): 795-798.
6. Nguyen AD, Herzog H, Sainsbury A. Neuropeptide Y and peptide YY: important regulators of energy metabolism. Curr Opin Endocrinol Diabetes Obes 2011; 18(1): 56-60.
7. Sederholm F, Ammar AA, Sodersten P. Intake inhibition by NPY: role of appetitive ingestive behavior and aversion. Physiol Behav 2002; 75(4): 567-575.
8. Ammar AA, Nergardh R, Fredholm BB, Brodin U, Sodersten P. Intake inhibition by NPY and CCK-8: A challenge of the notion of NPY as an "Orexigen". Behav Brain Res 2005; 161(1): 82-87.
9. Nergardh R, Ammar A, Brodin U, Bergstrom J, Scheurink A, Sodersten P. Neuropeptide Y facilitates activity-based-anorexia. Psychoneuroendocrinology 2007; 32(5): 493-502.
10. Holtkamp K, Herpertz-Dahlmann B, Mika C, et al. Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa. J Clin Endocrinol Metab 2003; 88(11): 5169-5174.
11. Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 2000; 85(10): 3803-3807.
12. Geliebter A, Hashim SA, Gluck ME. Appetite-related gut peptides, ghrelin, PYY, and GLP-1 in obese women with and without binge eating disorder (BED). Physiol Behav 2008; 94(5): 696-699.
13. Nedvidkova J, Krykorkova I, Bartak V, et al. Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J Clin Endocrinol Metab 2003; 88(4): 1678-1682.
14. Troisi A, Di Lorenzo G, Lega I, et al. Plasma ghrelin in anorexia, bulimia, and binge-eating disorder: relations with eating patterns and circulating concentrations of cortisol and thyroid hormones. Neuroendocrinology 2005; 81(4): 259-266.
15. Janas-Kozik M, Krupka-Matuszczyk I, Malinowska-Kolodziej I, Lewin-Kowalik J. Total ghrelin plasma level in patients with the restrictive type of anorexia nervosa. Regul Pept 2007; 140(1-2): 43-46.
16. Dostalova I, Haluzik M. The role of ghrelin in the regulation of food intake in patients with obesity and anorexia nervosa. Physiol Res 2009; 58(2): 159-170.
17. Sainsbury A, Cooney GJ, Herzog H. Hypothalamic regulation of energy homeostasis. Best Pract Res Clin Endocrinol Metab 2002; 16(4): 623-637.
18. Hokfelt T, Broberger C, Zhang X, et al. Neuropeptide Y: some viewpoints on a multifaceted peptide in the normal and diseased nervous system. Brain Res Brain Res Rev 1998; 26(2/3): 154-166.
19. Lin EJ, Sainsbury A, Lee NJ, et al. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology 2006; 147(11): 5094-5101.
20. Dube MG, Xu B, Crowley WR, Kalra PS, Kalra SP. Evidence that neuropeptide Y is a physiological signal for normal food intake. Brain Res 1994; 646(2): 341-344.
21. Motulsky HJ, Michel MC. Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am J Physiol 1988; 255(6 Pt 1): E880-E885.
22. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 1992; 89(13): 5794-5798.
23. Zhu J, Li W, Toews ML, Hexum TD. Neuropeptide Y inhibits forskolin-stimulated adenylate cyclase in bovine adrenal chromaffin cells via a pertussis toxin-sensitive process. J Pharmacol Exp Ther 1992; 263(3): 1479-1486.
24. Selbie LA, Darby K, Schmitz-Peiffer C, et al. Synergistic interaction of Y1-neuropeptide Y and alpha 1b-adrenergic receptors in the regulation of phospholipase C, protein kinase C, and arachidonic acid production. J Biol Chem 1995; 270(20): 11789-11796.
25. Sun QQ, Huguenard JR, Prince DA. Neuropeptide Y receptors differentially modulate G-protein-activated inwardly rectifying K+ channels and high-voltage-activated Ca2+ channels in rat thalamic neurons. J Physiol 2001; 531(Pt 1): 67-79.
26. Bleakman D, Colmers WF, Fournier A, Miller RJ. Neuropeptide Y inhibits Ca2+ influx into cultured dorsal root ganglion neurones of the rat via a Y2 receptor. Br J Pharmacol 1991; 103(3): 1781-1789.
27. Aakerlund L, Gether U, Fuhlendorff J, Schwartz TW, Thastrup O. Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett 1990; 260(1): 73-78.
28. Xiong Z, Cheung DW. Neuropeptide Y inhibits Ca(2+)-activated K+ channels in vascular smooth muscle cells from the rat tail artery. Pflugers Arch 1994; 429(2): 280-284.
29. Blomqvist AG, Herzog H. Y-receptor subtypes--how many more? Trends Neurosci 1997; 20(7): 294-298.
30. Herzog H. Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models. Eur J Pharmacol 2003; 480(1/3): 21-29.
31. Zhang L, Lee NJ, Nguyen AD, et al. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab 2010 Jul; 12(7): 591-603.
32. Howell OW, Doyle K, Goodman JH, et al. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem 2005; 93(3): 560-570.
33. Wheway J, Herzog H, Mackay F. The Y1 receptor for NPY: a key modulator of the adaptive immune system. Peptides 2007; 28(2): 453-458.
34. Bhisikar SM, Kokare DM, Nakhate KT, Chopde CT, Subhedar NK. Tolerance to ethanol sedation and withdrawal hyper-excitability is mediated via neuropeptide Y Y1 and Y5 receptors. Life Sci 2009; 85(21/22): 765-772.
35. Smith-White MA, Hardy TA, Brock JA, Potter EK. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 2001; 132(4): 861-868.
36. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418(6898): 650-654.
37. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13(7): 803-811.
38. Smith-White MA, Herzog H, Potter EK. Cardiac function in neuropeptide Y Y4 receptor-knockout mice. Regul Pept 2002 Dec 31; 110(1): 47-54.
39. Lin S, Shi YC, Yulyaningsih E, et al. Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptideinduced reduction in food intake in mice. PLoS One 2009; 4(12): e8488.
40. Sainsbury A, Schwarzer C, Couzens M, et al. Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev 2002; 16(9): 1077-1088.
41. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996; 382(6587): 168-171.
42. Mashiko S, Moriya R, Ishihara A, et al. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Eur J Pharmacol 2009; 615(1/3): 113-117.
43. Grundemar L, Wahlestedt C, Reis DJ. Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem. J Pharmacol Exp Ther 1991; 258(2): 633-638.
44. Gregor P, Feng Y, DeCarr LB, Cornfield LJ, McCaleb ML. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J Biol Chem 1996; 271(44): 27776-27781.
45. Rose PM, Fernandes P, Lynch JS, et al. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem 1995; 270(39): 22661-22664.
46. Matsumoto M, Nomura T, Momose K, et al. Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. J Biol Chem 1996; 271(44): 27217-27220.
47. Rose PM, Lynch JS, Frazier ST, et al. Molecular genetic analysis of a human neuropeptide Y receptor. The human homolog of the murine "Y5" receptor may be a pseudogene. J Biol Chem 1997; 272(6): 3622-3627.
48. Weinberg DH, Sirinathsinghji DJ, Tan CP, et al. Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem 1996; 271(28): 16435-8.
49. Hort Y, Baker E, Sutherland GR, Shine J, Herzog H. Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1. Genomics 1995; 26(1): 77-83.
50. Boey D, Sainsbury A, Herzog H. The role of peptide YY in regulating glucose homeostasis. Peptides 2007; 28(2): 390-395.
51. Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med 1993; 202(1): 44-63.
52. Grandt D, Teyssen S, Schimiczek M, et al. Novel generation of hormone receptor specificity by amino terminal processing of peptide YY. Biochem Biophys Res Commun 1992; 186(3): 1299-1306.
53. Essah PA, Levy JR, Sistrun SN, Kelly SM, Nestler JE. Effect of macronutrient composition on postprandial peptide YY levels. J Clin Endocrinol Metab 2007; 92(10): 4052-405s5.
54. Wang DH, Hu YS, Du JJ, Hu YY, Zhong WD, Qin WJ. Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway. Endocrine 2009; 35(1): 112-117.
55. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelinlike immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86(10): 4753-4758.
56. Misra M, Prabhakaran R, Miller KK, et al. Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J Clin Endocrinol Metab 2008; 93(4): 1292-1297.
57. Acosta A, Hurtado MD, Gorbatyuk O, et al. Salivary PYY: A Putative Bypass to Satiety. PLoS One 2011; 6(10): e26137.
58. Cox HM, Tough IR, Woolston AM, et al. Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab 2010; 11(6): 532-542.
59. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23(22): 7973-7981.
60. Lluis F, Gomez G, Fujimura M, Greeley GH, Jr., Thompson JC. Peptide YY inhibits nutrient-, hormonal-, and vagally-stimulated pancreatic exocrine secretion. Pancreas 1987; 2(4): 454-462.
61. Boey D, Heilbronn L, Sainsbury A, et al. Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptides 2006; 40(5): 317-324.
62. Boey D, Lin S, Karl T, et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006; 49(6): 1360-1370.
63. Yuzuriha H, Inui A, Asakawa A, et al. Gastrointestinal hormones(anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development. FASEB J 2007; 21(9): 2108-2112.
64. Boey D, Lin S, Enriquez RF, et al. PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides 2008; 42(1): 19-30.
65. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349(10): 941-948.
66. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409(6817): 194-198.
67. Gutierrez JA, Solenberg PJ, Perkins DR, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 2008; 105(17): 6320-6325.
68. Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatinproducing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 2003; 144(2): 544-551.
69. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37(4): 649-661.
70. Egecioglu E, Stenstrom B, Pinnock SB, et al. Hypothalamic gene expression following ghrelin therapy to gastrectomized rodents. Regul Pept 2008; 146(1/3): 176-182.
71. Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002; 123(4): 1120-1128.
72. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004; 145(6): 2607-2612.
73. Olszewski PK, Schioth HB, Levine AS. Ghrelin in the CNS: from hunger to a rewarding and memorable meal? Brain Res Rev 2008 Jun; 58(1): 160-170.
74. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50(8): 1714-1719.
75. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004; 287(2): E297-E304.
76. Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab 2004; 89(3): 1319-1324.
77. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin--a hormone with multiple functions. Front Neuroendocrinol 2004; 25(1): 27-68.
78. Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006 Aug 30; 89(1): 71-84.
79. Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002; 277(7): 5667-5674.
80. Dezaki K, Hosoda H, Kakei M, et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes 2004; 53(12): 3142-3151.
81. Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucosestimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010; 59(9): 2145-21451.
82. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407(6806): 908-913.
83. Davies JS, Kotokorpi P, Eccles SR, et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol 2009 Jun; 23(6): 914-924.
84. Kaye WH, Berrettini WH, Gwirtsman HE, et al. Contribution of CNS neuropeptide (NPY, CRH, and beta-endorphin) alterations to psychophysiological abnormalities in anorexia nervosa. Psychopharmacol Bull 1989; 25(3): 433-438.
85. von Zastrow M. Endocytosis and downregulation of G proteincoupled receptors. Parkinsonism Relat Disord 2001; 7(3): 265-271.
86. Thompson MD, Siminovitch KA, Cole DE. G protein-coupled receptor pharmacogenetics. Methods Mol Biol 2008; 448: 139-185.
87. Kargl J, Balenga N, Platzer W, Martini L, Whistler J, Waldhoer M. The GPCR - associated sorting protein 1 regulates ligand-induced downregulation of GPR55. Br J Pharmacol 2011 Jun 30.
88. Ammar AA, Sederholm F, Saito TR, Scheurink AJ, Johnson AE, Sodersten P. NPY-leptin: opposing effects on appetitive and consummatory ingestive behavior and sexual behavior. Am J Physiol Regul Integr Comp Physiol 2000; 278(6): R1627-R16233.
89. Tappe KA, Gerberg SE, Shide DJ, Andersen AE, Rolls BJ. Videotape assessment of changes in aberrant meal-time behaviors in anorexia nervosa after treatment. Appetite 1998; 30(2): 171-184.
90. Lewis DE, Shellard L, Koeslag DG, et al. Intense exercise and food restriction cause similar hypothalamic neuropeptide Y increases in rats. Am J Physiol 1993; 264(2 Pt 1): E279-E284.
91. Routtenberg A, Kuznesof AW. Self-starvation of rats living in activity wheels on a restricted feeding schedule. J Comp Physiol Psychol 1967; 64(3): 414-421.
92. Munglani R, Hudspith MJ, Hunt SP. The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. Drugs 1996; 52(3): 371-389.
93. Oswiecimska J, Ziora K, Geisler G, Broll-Waska K. Prospective evaluation of leptin and neuropeptide Y (NPY) serum levels in girls with anorexia nervosa. Neuro Endocrinol Lett 2005; 26(4): 301-304.
94. Baranowska B, Wolinska-Witort E, Wasilewska-Dziubinska E, Roguski K, Martynska L, Chmielowska M. The role of neuropeptides in the disturbed control of appetite and hormone secretion in eating disorders. Neuro Endocrinol Lett 2003; 24(6): 431-434.
95. Makarenko IG, Meguid MM, Gatto L, Chen C, Ugrumov MV. Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia. Brain Res 2003; 961(1): 100-108.
96. Makarenko IG, Meguid MM, Gatto L, et al. Normalization of hypothalamic serotonin (5-HT 1B) receptor and NPY in cancer anorexia after tumor resection: an immunocytochemical study. Neurosci Lett 2005; 383(3): 322-327.
97. Meguid MM, Ramos EJ, Laviano A, et al. Tumor anorexia: effects on neuropeptide Y and monoamines in paraventricular nucleus. Peptides 2004; 25(2): 261-266.
98. Chance WT, Xiao C, Dayal R, Sheriff S. Alteration of NPY and Y1 receptor in dorsomedial and ventromedial areas of hypothalamus in anorectic tumor-bearing rats. Peptides 2007; 28(2): 295-301.
99. Jatoi A, Loprinzi CL, Sloan JA, Klee GG, Windschitl HE. Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation. Cancer 2001; 92(3): 629-633.
100. McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994; 265(1-2): 99-102.
101. Lawson EA, Eddy KT, Donoho D, et al. Appetite-regulating hormones cortisol and peptide YY are associated with disordered eating psychopathology, independent of body mass index. Eur J Endocrinol 2011; 164(2): 253-261.
102. Otto B, Cuntz U, Otto C, Heldwein W, Riepl RL, Tschop MH. Peptide YY release in anorectic patients after liquid meal. Appetite 2007; 48(3): 301-304.
103. Nakahara T, Kojima S, Tanaka M, et al. Incomplete restoration of the secretion of ghrelin and PYY compared to insulin after food ingestion following weight gain in anorexia nervosa. J Psychiatr Res 2007; 41(10): 814-820.
104. Misra M, Miller KK, Tsai P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2006; 91(3): 1027-1033.
105. Abid K, Rochat B, Lassahn PG, et al. Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein. J Biol Chem 2009; 284(37): 24715-24724.
106. Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006; 4(3): 223-233.
107. Fisher M, Golden NH, Katzman DK, et al. Eating disorders in adolescents: a background paper. J Adolesc Health 1995; 16(6): 420-437.
108. Fernandez-Fernandez R, Aguilar E, Tena-Sempere M, Pinilla L. Effects of polypeptide YY(3-36) upon luteinizing hormonereleasing hormone and gonadotropin secretion in prepubertal rats: in vivo and in vitro studies. Endocrinology 2005; 146(3): 1403-1410.
109. Tovar SA, Seoane LM, Caminos JE, Nogueiras R, Casanueva FF, Dieguez C. Regulation of peptide YY levels by age, hormonal, and nutritional status. Obes Res 2004; 12(12): 1944-1950.
110. Lloyd B, Ravi P, Mendes N, Klibanski A, Misra M. Peptide YY levels across pubertal stages and associations with growth hormone. J Clin Endocrinol Metab 2010; 95(6): 2957-2962.
111. Evans S, Pamuklar Z, Rosko J, et al. Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction. Surg Endosc 2011 Nov 2.
112. Chelikani PK, Shah IH, Taqi E, Sigalet DL, Koopmans HH. Comparison of the effects of Roux-en-Y gastric bypass and ileal transposition surgeries on food intake, body weight, and circulating peptide YY concentrations in rats. Obes Surg 2010; 20(9): 1281-1288.
113. Usdan LS, Khaodhiar L, Apovian CM. The endocrinopathies of anorexia nervosa. Endocr Pract 2008; 14(8): 1055-1063.
114. Misra M, Miller KK, Kuo K, et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005; 289(2): E347-E356.
115. Prince AC, Brooks SJ, Stahl D, Treasure J. Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hormones to food in eating disorders. Am J Clin Nutr 2009; 89(3): 755-765.
116. Broglio F, Gianotti L, Destefanis S, et al. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol (Oxf) 2004; 60(5): 592-599.
117. Miljic D, Pekic S, Djurovic M, et al. Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa. J Clin Endocrinol Metab 2006; 91(4): 1491-1495.
118. Haas V, Onur S, Paul T, et al. Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery. Am J Clin Nutr 2005; 81(4): 889-896.
119. Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145(5): 669-673.
120. Takahashi M, Terashima M, Takagane A, Oyama K, Fujiwara H, Wakabayashi G. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int J Clin Oncol 2009; 14(4): 315-320.
121. Wang HS, Oh DS, Ohning GV, Pisegna JR. Elevated serum ghrelin exerts an orexigenic effect that may maintain body mass index in patients with metastatic neuroendocrine tumors. J Mol Neurosci 2007; 33(3): 225-231.
122. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90(5): 2920-2926.
123. Long CL. Measurement of resting metabolic expenditure. JPEN J Parenter Enteral Nutr 1992; 16(2): 193-194.
124. Williams DL, Grill HJ, Cummings DE, Kaplan JM. Overfeedinginduced weight gain suppresses plasma ghrelin levels in rats. J Endocrinol Invest 2006; 29(10): 863-868.
125. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310(5750): 996-999.
126. Monteleone P, Tortorella A, Castaldo E, Di Filippo C, Maj M. No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene with anorexia nervosa or bulimia nervosa. Neurosci Lett 2006; 398(3): 325-327.
127. Lagaud GJ, Young A, Acena A, Morton MF, Barrett TD, Shankley NP. Obestatin reduces food intake and suppresses body weight gain in rodents. Biochem Biophys Res Commun 2007; 357(1): 264-269.
128. Gourcerol G, Coskun T, Craft LS, et al. Preproghrelin-derived peptide, obestatin, fails to influence food intake in lean or obese rodents. Obesity (Silver Spring) 2007; 15(11): 2643-2652.
129. Germain N, Galusca B, Grouselle D, et al. Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. Psychoneuroendocrinology 2009; 34(3): 413-419.
130. Sedlackova D, Dostalova I, Hainer V, et al. Simultaneous decrease of plasma obestatin and ghrelin levels after a high-carbohydrate breakfast in healthy women. Physiol Res 2008; 57 Suppl 1: S29-S37.
131. Zamrazilova H, Hainer V, Sedlackova D, et al. Plasma obestatin levels in normal weight, obese and anorectic women. Physiol Res 2008; 57 Suppl 1: S49-S55.
132. Kohno D, Nakata M, Maekawa F, et al. Leptin suppresses ghrelininduced activation of neuropeptide Y neurons in the arcuate nucleus via phosphatidylinositol 3-kinase- and phosphodiesterase 3-mediated pathway. Endocrinology 2007; 148(5): 2251-2263.
133. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24(6): RC19-RC21.
134. Foster-Schubert KE, Overduin J, Prudom CE, et al. Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates. J Clin Endocrinol Metab 2008; 93(5): 1971-1979.
135. Overduin J, Frayo RS, Grill HJ, Kaplan JM, Cummings DE. Role of the duodenum and macronutrient type in ghrelin regulation. Endocrinology 2005; 146(2): 845-850.
136. Blom WA, Lluch A, Stafleu A, et al. Effect of a high-protein breakfast on the postprandial ghrelin response. Am J Clin Nutr 2006; 83(2): 211-220.
137. Tanaka M, Miyazaki T, Yamamoto I, et al. Molecular characterization of chicken growth hormone secretagogue receptor gene. Gen Comp Endocrinol 2003; 134(2): 198-202.
138. Harada T, Nakahara T, Yasuhara D, et al. Obestatin, acyl ghrelin, and des-acyl ghrelin responses to an oral glucose tolerance test in the restricting type of anorexia nervosa. Biol Psychiatry 2008; 63(2): 245-247.
139. Stock S, Leichner P, Wong AC, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005; 90(4): 2161-2168.
140. Karczewska-Kupczewska M, Straczkowski M, Adamska A, et al. Increased suppression of serum ghrelin concentration by hyperinsulinemia in women with anorexia nervosa. Eur J Endocrinol 2010; 162(2): 235-239.
141. Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 2000; 133(10): 790-794.
142. Wong S, Au B, Lau E, Lee Y, Sham A, Lee S. Osteoporosis in Chinese patients with anorexia nervosa. Int J Eat Disord 2004; 36(1): 104-108.
143. Lawson EA, Miller KK, Bredella MA, et al. Hormone predictors of abnormal bone microarchitecture in women with anorexia nervosa. Bone 2010; 46(2): 458-463.
144. Cobb KL, Bachrach LK, Greendale G, et al. Disordered eating, menstrual irregularity, and bone mineral density in female runners. Med Sci Sports Exerc 2003; 35(5): 711-719.
145. Mehler PS, Sabel AL, Watson T, Andersen AE. High risk of osteoporosis in male patients with eating disorders. Int J Eat Disord 2008; 41(7): 666-672.
146. Driessler F, Baldock PA. Hypothalamic regulation of bone. J Mol Endocrinol 2010 Oct; 45(4): 175-181.
147. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111(3): 305-317.
148. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005; 434(7032): 514-520.
149. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002; 109(7): 915-921.
150. Baldock PA, Lee NJ, Driessler F, et al. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 2009; 4(12): e8415.
151. Lee NJ, Doyle KL, Sainsbury A, et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J Bone Miner Res 2010; 25(8): 1736-47.
152. Baldock PA, Allison SJ, Lundberg P, et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007; 282(26): 19092-19102.
153. Baldock PA, Sainsbury A, Allison S, et al. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J Bone Miner Res 2005 Oct; 20(10): 1851-1857.
154. Ahmed M, Bjurholm A, Kreicbergs A, Schultzberg M. Neuropeptide Y, tyrosine hydroxylase and vasoactive intestinal polypeptide-immunoreactive nerve fibers in the vertebral bodies, discs, dura mater, and spinal ligaments of the rat lumbar spine. Spine (Phila Pa 1976) 1993; 18(2): 268-273.
155. Sisask G, Bjurholm A, Ahmed M, Kreicbergs A. The development of autonomic innervation in bone and joints of the rat. J Auton Nerv Syst 1996; 59(1/2): 27-33.
156. Hill EL, Elde R. Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res 1991; 264(3): 469-480.
157. Lundberg JM, Martinsson A, Hemsen A, et al. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun 1985; 133(1): 30-36.
158. Kempna P, Korner M, Waser B, et al. Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors. Mol Cell Endocrinol 2010; 314(1): 101-109.
159. Igwe JC, Jiang X, Paic F, et al. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem 2009; 108(3): 621-630.
160. Lee NJ, Nguyen AD, Enriquez RF, et al. Osteoblast specific Y1 receptor deletion enhances bone mass. Bone 2011; 48(3): 461-467.
161. McMinn JE, Seeley RJ, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW. NPY-induced overfeeding suppresses hypothalamic NPY mRNA expression: potential roles of plasma insulin and leptin. Regul Pept 1998; 75-76: 425-431.
162. Sipols AJ, Baskin DG, Schwartz MW. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 1995; 44(2): 147-151.
163. Lin S, Storlien LH, Huang XF. Leptin receptor, NPY, POMC mRNA expression in the diet-induced obese mouse brain. Brain research 2000; 875(1/2): 89-95.
164. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev 1998 Feb; 19(1): 55-79.
165. Fukushima N, Hanada R, Teranishi H, et al. Ghrelin directly regulates bone formation. J Bone Miner Res 2005; 20(5): 790-798.
166. Maccarinelli G, Sibilia V, Torsello A, et al. Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol 2005; 184(1): 249-256.
167. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 2004; 101(13): 4679-4684.
168. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87(1): 240-244.
169. Russell M, Stark J, Nayak S, et al. Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. Bone 2009; 45(1): 104-109.
170. Delhanty PJ, van der Eerden BC, van der Velde M, et al. Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3- kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol 2006; 188(1): 37-47.
171. Pacifico L, Anania C, Poggiogalle E, et al. Relationships of acylated and des-acyl ghrelin levels to bone mineralization in obese children and adolescents. Bone 2009; 45(2): 274-279.
172. Jurimae J, Cicchella A, Tillmann V, et al. Effect of pubertal development and physical activity on plasma ghrelin concentration in boys. J Endocrinol Invest 2009; 32(1): 18-22.